Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.

Trial Details

NCT ID
NCT06116682
Phase
PHASE2
Sponsor
SWOG Cancer Research Network
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Amivantamab
  • Biospecimen Collection
  • Computed Tomography
  • Magnetic Resonance Imaging
Locations (sample)
  • Jonesboro, Arkansas, United States|35.8423,-90.70428
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Auburn, California, United States|38.89657,-121.07689
  • Berkeley, California, United States|37.87159,-122.27275
  • Fremont, California, United States|37.54827,-121.98857

Key Eligibility Criteria

  • Participants must have been assigned to S1900J by the Southwest Oncology Group (SWOG) Statistics and Data Management Center (SDMC). Assignment to S…
  • Participants must have documentation of NSCLC with MET amplification determined by FMI tissue-based next generation sequencing (NGS) assay
  • Participants must have measurable disease documented by CT or MRI. The CT from a combined positron emission tomography (PET)/CT may be used to docu…
  • Participants must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to sub-study registr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →